Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | VNN1 | O95497 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 4/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 4/20 | 0.41 |
| ▸ | SLC26A6 | Q9BXS9 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.40 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540825 | 0.91 | LMNA (0.46) | LMNAPTGS2CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5540554 | 0.83 | LMNA (0.39) | LMNAPDE4BTP53POLBMAPK1 | |
| SCHEMBL15163611 | 0.82 | PTGS2 (0.38) | LMNAPTGS2PTGS1 | |
| SCHEMBL5004713 | 0.82 | LMNA (0.44) | LMNAPDE4BTP53POLB | |
| SCHEMBL5538446 | 0.82 | ALDH1A1 (0.40) | LMNAPTGS2PDE4BKCNQ3KCNQ2 | |
| SCHEMBL5545678 | 0.81 | MAPT (0.42) | LMNAPTGS2PDE4BKCNQ3KCNQ2 | |
| SCHEMBL5540936 | 0.81 | KCNQ3 (0.41) | LMNAPTGS2PDE4BKCNQ3KCNQ2 | |
| SCHEMBL5545753 | 0.79 | LMNA (0.46) | LMNAKCNQ3KCNQ2TP53POLB | |
| SCHEMBL5538554 | 0.78 | PTGS2 (0.39) | LMNAPTGS2PTGS1CYP2C19 | |
| SCHEMBL14072834 | 0.78 | LMNA (0.40) | LMNAPDE4BPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| EP-1720856-B1 | HIV INTEGRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-08-14 | — | — | EP | disclosed |
| CN-1976915-A | HIV integrase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2007-06-06 | — | — | CN | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
| EP-1720856-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077050-A2 | HIV INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | BCDIN3D, DUT, SAMHD1 | LMNA 3503/4885VNN1 343/4885PTGS2 4168/4885 |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | LMNA 4134/4885VNN1 1054/4885PTGS2 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.